Medford, MA, United States of America

Benjamin Kleinstiver

USPTO Granted Patents = 28 

 

Average Co-Inventor Count = 2.4

ph-index = 9

Forward Citations = 345(Granted Patents)


Location History:

  • Medford, MA (US) (2016 - 2023)
  • Boston, MA (US) (2024)

Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
28 patents (USPTO):Explore Patents

Title: Innovator Profile: Benjamin Kleinstiver

Introduction

Benjamin Kleinstiver, based in Medford, MA, is a distinguished inventor known for his significant contributions to the field of genomic engineering. With an impressive portfolio of 25 patents, he has made remarkable strides in advancing biotechnology and gene editing technologies. His innovative work has garnered attention and recognition in the scientific community, positioning him as a leading figure in genetic research.

Latest Patents

Among his latest patents, Kleinstiver has developed pioneering technologies such as "Engineered CRISPR-Cas9 nucleases with altered PAM specificity" and "Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf1." These patents focus on enhancing the specificity of CRISPR-Cas9 nucleases for genomic and epigenomic engineering and enabling drug-inducible and multiplexable gene regulation. His work is expected to have far-reaching implications in the field of genetic engineering and medicine.

Career Highlights

Kleinstiver is currently affiliated with the General Hospital Corporation, where he collaborates with other leading scientists to push the boundaries of genetic research. His career is marked by a commitment to innovation, leading him to develop technologies that improve gene editing precision and versatility. His contributions in this field have not only expanded the scientific toolkit available for researchers but also opened new pathways for therapeutic applications.

Collaborations

Throughout his career, Benjamin Kleinstiver has collaborated with notable scientists, including J Keith Joung and Vikram Pattanayak. These collaborations have fueled groundbreaking research and have played a critical role in the development of advanced gene editing techniques that are shaping the future of molecular biology and medicine. Together, they continue to explore the possibilities of CRISPR technology to revolutionize genome targeting and gene regulation.

Conclusion

Benjamin Kleinstiver is an emerging leader in the field of biotechnology, with a robust patent portfolio that reflects his commitment to innovation and excellence. With ongoing collaborations and groundbreaking research, he is poised to contribute significantly to the advancement of genetic engineering, making profound impacts on health and medicine for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…